Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.

× No keyword cloud information.

10 in total

1. Two Randomized Clinical Trials on the Treatment of Secondary Mitral Regurgitation-Contradictory or Complementary?

Authors: Gilbert H L Tang; Subodh Verma; Deepak L Bhatt
Journal: JAMA Cardiol Date: 2019-04-01 Impact factor: 14.676

Review 2. Cardiorenal syndrome in heart failure with preserved ejection fraction-an under-recognized clinical entity.

Authors: Akanksha Agrawal; Mario Naranjo; Napatt Kanjanahattakij; Janani Rangaswami; Shuchita Gupta
Journal: Heart Fail Rev Date: 2019-07 Impact factor: 4.214

3. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.

Authors: Subodh Verma; Stephen C Bain; John B Buse; Thomas Idorn; Søren Rasmussen; David D Ørsted; Michael A Nauck
Journal: JAMA Cardiol Date: 2019-12-01 Impact factor: 14.676

4. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Authors: Takayoshi Kanie; Atsushi Mizuno; Yoshimitsu Takaoka; Takahiro Suzuki; Daisuke Yoneoka; Yuri Nishikawa; Wilson Wai San Tam; Jakub Morze; Andrzej Rynkiewicz; Yiqiao Xin; Olivia Wu; Rui Providencia; Joey Sw Kwong
Journal: Cochrane Database Syst Rev Date: 2021-10-25

5. Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes.

Authors: Daniella C Terenzi; Mohammed Al-Omran; Adrian Quan; Hwee Teoh; Subodh Verma; David A Hess
Journal: JACC Basic Transl Sci Date: 2018-11-05

6. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.

Authors: Subodh Verma; Stephen C Bain; Tea Monk Fries; C David Mazer; Michael A Nauck; Richard E Pratley; Søren Rasmussen; Hans A Saevereid; Bernard Zinman; John B Buse
Journal: Diabetes Obes Metab Date: 2019-04-02 Impact factor: 6.577

Review 7. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs.

Authors: Eleftheria Galatou; Elena Mourelatou; Sophia Hatziantoniou; Ioannis S Vizirianakis
Journal: Antioxidants (Basel) Date: 2022-05-27

8. Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers.

Authors: John Climax; Philip N Newsome; Moayed Hamza; Markus Weissbach; David Coughlan; Naveed Sattar; Darren K McGuire; Deepak L Bhatt
Journal: J Am Heart Assoc Date: 2020-08-11 Impact factor: 5.501

9. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.

Authors: Lawrence A Leiter; Stephen C Bain; Deepak L Bhatt; John B Buse; C David Mazer; Richard E Pratley; Søren Rasmussen; Maria Sejersten Ripa; Hrvoje Vrazic; Subodh Verma
Journal: Diabetes Obes Metab Date: 2020-06-03 Impact factor: 6.577

10. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.

Authors: Subodh Verma; Mohammed Al-Omran; Lawrence A Leiter; C David Mazer; Søren Rasmussen; Hans A Saevereid; Maria Sejersten Ripa; Marc P Bonaca
Journal: Diabetes Obes Metab Date: 2022-04-11 Impact factor: 6.408

10 in total